BIOATLA, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
BIOATLA, INC. (BCAB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 365.42 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- BIOATLA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 369.67K shares, a 1.65% decline year-over-year.
- BIOATLA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 375.88K shares, a 95.31% decline year-over-year.
- BIOATLA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 8.01M shares, a 18.88% increase year-over-year.
- BIOATLA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 6.74M shares, a 101.60% increase year-over-year.
- BIOATLA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 24.89M shares, a 42.98% increase from fiscal 2024.
- BIOATLA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 17.41M shares, a 170.72% increase from fiscal 2023.
- BIOATLA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 6.43M shares, a 97.22% increase from fiscal 2022.
- BIOATLA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 3.26M shares, a 47.32% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 365.42K shares 10-Q · filed 2026-08-13 | |||||
| 2026-03-31 | 369.67K shares 10-Q · filed 2026-05-15 | |||||
| 2025-12-31 | 24.89M shares 10-K · filed 2026-03-31 | |||||
| 2025-09-30 | 18.19M shares 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | 365.33K shares 10-Q · filed 2026-08-13 | 18.27M shares 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | 375.88K shares 10-Q · filed 2026-05-15 | 18.79M shares 10-Q · filed 2025-05-06 | ||||
| 2024-12-31 | 17.41M shares 10-K · filed 2026-03-31 | |||||
| 2024-09-30 | 7.88M shares 10-Q · filed 2025-11-13 | |||||
| 2024-06-30 | 7.93M shares 10-Q · filed 2025-08-07 | |||||
| 2024-03-31 | 8.01M shares 10-Q · filed 2025-05-06 | |||||
| 2023-12-31 | 6.43M shares 10-K · filed 2025-03-28 | |||||
| 2023-09-30 | 6.65M shares 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | 6.88M shares 10-Q · filed 2024-08-08 | |||||
| 2023-03-31 | 6.74M shares 10-Q · filed 2024-05-14 | |||||
| 2022-12-31 | 3.26M shares 10-K · filed 2024-03-26 | |||||
| 2022-09-30 | 3.46M shares 10-Q · filed 2023-11-07 | |||||
| 2022-06-30 | 3.51M shares 10-Q · filed 2023-08-01 | |||||
| 2022-03-31 | 3.34M shares 10-Q · filed 2023-05-11 | |||||
| 2021-12-31 | 2.21M shares 10-K · filed 2023-03-23 | |||||
| 2021-09-30 | 3.27M shares 10-Q · filed 2022-11-04 | |||||
| 2021-06-30 | 3.35M shares 10-Q · filed 2022-08-09 | |||||
| 2021-03-31 | 3.28M shares 10-Q · filed 2022-05-05 | |||||
| 2020-12-31 | 3.25M shares 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |